Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06967805 · ClinicalTrials.gov registry record · Phase 2

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Mediar Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
164
Enrollment target
20
Study locations

NCT06967805 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that is actively recruiting participants, run by Mediar Therapeutics. The registered enrollment target is 164 participants, below the 748-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06967805, a Phase 2 study of Idiopathic Pulmonary Fibrosis, is actively recruiting participants, sponsored by Mediar Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
164 participants
Enrollment target
20
Study locations

Study Summary

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

Conditions Studied

Idiopathic Pulmonary Fibrosis

Interventions

  • OTHER Placebo
  • BIOLOGICAL MTX-463

Study Locations (20)

California

  • WISPer Site in Los Angeles, CA - Los Angeles
  • WISPer site in Newport Beach, CA - Newport Beach
  • WISPer Site in Palm Springs, CA - Palm Springs

Michigan

  • WISPer Site in Ann Arbor, MI - Ann Arbor
  • WISPer Site in Detroit, MI - Detroit

North Carolina

  • WISPer Site in Durham, NC - Durham
  • WISPer site in Greensboro, NC - Greensboro

Alabama

  • WISPer Site in Birmingham, AL - Birmingham

Arizona

  • WISPer site in Phoenix, AZ - Phoenix

Colorado

  • WISPer Site in Denver, CO - Denver

Florida

  • WISPer site in Loxahatchee, FL - Loxahatchee Groves

Illinois

  • WISPer site in Champaign, IL - Champaign

Trial Details

FieldValue
Enrollment Target 164 participants
Start Date 2025-05-05
Est. Completion 2027-08
Phase Phase 2

Sponsor

Mediar Therapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06967805

The ClinicalTrials.gov registry entry for NCT06967805 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 748-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (78% lower). The listed sponsor is Mediar Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06967805 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Michigan, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06967805 about?

NCT06967805 is a clinical study titled "WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)". A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

What is the current status of trial NCT06967805?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2025-05-05. Estimated completion is 2027-08.

What conditions does trial NCT06967805 study?

This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.

What interventions are being tested in trial NCT06967805?

The interventions under investigation include: Placebo (OTHER), MTX-463 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06967805?

This trial is sponsored by Mediar Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06967805 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Pulmonary Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Idiopathic Pulmonary Fibrosis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.